IMNM Immunome, Inc.
$18.77▲ +4.92%
Healthcare
Other
Volume 1.23M
Avg Volume (10D) 1.41M
Key Metrics & Fundamentals
Market Cap
$2.21B
P/E Ratio
–
Div Yield
0.00%
52W Range
14.64 - 30.06
% vs 50 MA
-18.55%
% vs 200 MA
-16.67%
RSI-14
42.9
MACD Histogram
+0.2700
Beta (1Y vs SPY)
1.62
Free Cash Flow
-$63.87M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$76.97M
COGS
–
Operating Exp
$78.14M
Operating Income
-$78.14M
EBIT
-$78.14M
Pretax Income
-$73.13M
Net Income
-$73.13M
EPS (Diluted)
-0.65
Price & Volume History
Loading chart…
Recent News
Immunome Presents Additional Clinical Data for Varegacestat in Desmoid Tumors at ESMO 2026
Business Wire · Oct 26, 2026 7:00 AM ET
William Blair Expands Biotech Research as Veteran Analyst Alethia Young Initiates Coverage
Business Wire · Oct 21, 2026 12:30 PM ET
William Blair Initiates Coverage on Immunome With Outperform Rating
MT Newswires · Oct 16, 2026 7:53 AM ET
Immunome (IMNM) Following FDA Clearance Is Its Oncology Story Back In Value Focus
Simply Wall St. · Oct 13, 2026 6:16 PM ET
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire · Oct 6, 2026 4:02 PM ET
Immunome (IMNM) Is Down 6.5% After FDA Clears IND For Novel ADC IM-1340 Trial – Has The Bull Case Changed?
Simply Wall St. · Oct 2, 2026 9:10 AM ET
Stifel Initiates Immunome at Hold With $24 Price Target
MT Newswires · Oct 1, 2026 6:06 AM ET
Immunome (IMNM) Stock Looks Near Fair Value As Its 186% Run Continues
Simply Wall St. · Oct 1, 2026 5:11 AM ET
Immunome Gets FDA Clearance for IM-1340 Clinical Trial in Advanced Solid Tumors
MT Newswires · Sep 30, 2026 8:36 AM ET
Immunome Announces IND Clearance for IM-1340, a Potential First-in-Class Antibody-Drug Conjugate for the Treatment of Solid Tumors
Business Wire · Sep 30, 2026 7:45 AM ET
Financial Overview - Income Statement
Quarterly
Jun 2025
See IMNM's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.